Last reviewed · How we verify
RSV vaccine GSK3003891A — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
RSV vaccine GSK3003891A (RSV vaccine GSK3003891A) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RSV vaccine GSK3003891A TARGET | RSV vaccine GSK3003891A | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RSV vaccine GSK3003891A CI watch — RSS
- RSV vaccine GSK3003891A CI watch — Atom
- RSV vaccine GSK3003891A CI watch — JSON
- RSV vaccine GSK3003891A alone — RSS
Cite this brief
Drug Landscape (2026). RSV vaccine GSK3003891A — Competitive Intelligence Brief. https://druglandscape.com/ci/rsv-vaccine-gsk3003891a. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab